Oragenics, Inc. Share Price & Technical Analysis

OGEN · $0.60 (+1.69%)

Healthcare / Biotechnology

AI Score 24 · Bearish

$0.60

+1.69%

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation wh

Price chart

AI snapshotScore 24/100

Bearish · Downtrend · Weak

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida.

Full AI Q&A, portfolio tracking, and live alerts in the app.

Key metrics

Market cap

$2.54M

P/E ratio

52W high

$9.60

52W low

$0.50

Volume

35,254

Beta

1.26

Related stocks in Healthcare

Frequently asked questions

What is Oragenics, Inc. share price today?
Oragenics, Inc. (OGEN) last traded around $0.60 on StockPro. Prices refresh every few minutes during market hours.
What technical signals does OGEN have?
StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for OGEN. Download the app for real-time alerts.
How can I analyze Oragenics, Inc. stock?
Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.

Explore more on StockPro